Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ First Phosphate Corp.: First Phosphate Announces Uplisting of American Depositary Receipt (ADR) to Nasdaq... (Newsfile) +++ FIRST PHOSPHATE Aktie +4,02%

MYRIAD GENETICS Aktie

 >MYRIAD GENETICS Aktienkurs 
2.8 EUR    +1.6%    (TradegateBSX)
Ask: 2.847 EUR / 1060 Stück
Bid: 2.783 EUR / 1080 Stück
Tagesumsatz: 231 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>MYRIAD GENETICS Performance
1 Woche: +13,0%
1 Monat: -45,4%
3 Monate: -21,3%
6 Monate: -35,2%
1 Jahr: -45,6%
laufendes Jahr: -47,7%
>MYRIAD GENETICS Aktie
Name:  MYRIAD GENETICS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US62855J1043 / 897518
Symbol/ Ticker:  MYD (Frankfurt) / MYGN (NASDAQ)
Kürzel:  FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN
Index:  -
Webseite:  https://myriad.com/
Profil:  Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagno..
>Volltext..
Marktkapitalisierung:  261.49 Mio. EUR
Unternehmenswert:  344.92 Mio. EUR
Umsatz:  700.04 Mio. EUR
EBITDA:  -35.93 Mio. EUR
Nettogewinn:  -97.72 Mio. EUR
Gewinn je Aktie:  -1.04 EUR
Schulden:  182.69 Mio. EUR
Liquide Mittel:  99.98 Mio. EUR
Operativer Cashflow:  6.68 Mio. EUR
Bargeldquote:  0.88
Umsatzwachstum:  -0.11%
Gewinnwachstum:  70.61%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  MYRIAD GENETICS
Letzte Datenerhebung:  08.08.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 95.65 Mio. St.
Frei handelbar: 93.02%
Rückkaufquote: -1.13%
Mitarbeiter: 2700
Umsatz/Mitarb.: 0.27 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 64%
Bewertung:
KGV: -
KGV lG: -
KUV: 0.35
KBV: 1.02
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 65.1%
Gewinnmarge: -13.96%
Operative Marge: -11.22%
Managementeffizenz:
Gesamtkaprendite: -17.11%
Eigenkaprendite: -32.54%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
04.08.26 - 16:09
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics (PR Newswire)
 
Myriad Genetics guided to adjusted gross margin of 68%-69% for 2026. Months later, the Company cut its revenue outlook, suspended EBITDA guidance, and MYGN shareholders absorbed the loss. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Myriad Genetics (NASDAQ: MYGN) investors are sitting on losses......
04.08.26 - 00:16
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) (PR Newswire)
 
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss. NEW YORK, Aug. 3, 2026 /PRNewswire/......
31.07.26 - 01:45
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
30.07.26 - 22:09
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability (GlobeNewswire EN)
 
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Scalability...
23.07.26 - 15:09
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 (GlobeNewswire EN)
 
Myriad Genetics will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026....
21.07.26 - 15:09
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen (GlobeNewswire EN)
 
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks...
17.07.26 - 18:00
AWHL vs. MYGN: Which Women′s Health Diagnostics Stock is Better Now? (Zacks)
 
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in....
23.06.26 - 15:09
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication (GlobeNewswire EN)
 
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD...
10.06.26 - 00:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Myriad Genetics im Wert von 66843 USD (Insiderkauf)
 
Kumar, Rashmi - Aufsichtsrat - Tag der Transaktion: 2026-06-08...
09.06.26 - 17:30
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? (Zacks)
 
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results....
02.06.26 - 15:09
Myriad Genetics Names Raj Jampa as New Chief Technology Officer (GlobeNewswire EN)
 
Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO)....
28.05.26 - 16:45
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh (Zacks)
 
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance....
28.05.26 - 16:45
Myriad Genetics′ Upcoming Prolaris + AI Test Debut May Lift Its Stock (Zacks)
 
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance....
27.05.26 - 15:09
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting (GlobeNewswire EN)
 
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting...
26.05.26 - 22:09
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) (GlobeNewswire EN)
 
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence...
15.05.26 - 17:03
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life (GlobeNewswire EN)
 
Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn...
15.05.26 - 02:02
Insiderhandel: Aufsichtsrat kauft Aktien von Myriad Genetics im Wert von 27638 USD (Insiderkauf)
 
Bisaro, Paul - Aufsichtsrat - Tag der Transaktion: 2026-05-14...
07.05.26 - 22:09
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire EN)
 
Myriad Genetics will participate in The BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference....
06.05.26 - 20:24
Myriad Genetics in record sell-off after Q1 miss (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 04:00
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was sein wird - wird sein. - Sprichwort Indien
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!